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TreatmentAbstract
Chediak–Higashi syndrome (CHS) is a rare autosomal recessive lysosomal disorder characterized
by frequent infections, oculocutaneous albinism, bleeding diathesis, and progressive neurologic
deterioration. In 85% of cases, CHS patients develop the accelerated phase characterized by
pancytopenia, high fever, and lymphohistiocytic infiltration of liver, spleen, and lymph nodes.
Treatment of accelerated-phase CHS is difficult and the prognosis is poor. Here, we report a case
of CHS in a 2-year-old boy who presented in the accelerated phase of the disease. CHS diagnosis
was made on the basis of clinical characteristics, hair analysis, and identification of
pathognomonic giant azurophilic granules in peripheral blood and bone marrow.
 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Chediak Higashi syndrome (CHS) is a rare autosomal
recessive disorder with fewer than 500 cases published
worldwide over the last 20 years [1]. The largest CHS study
to date included 15 patients [2]. In Tunisia, Bouatay et al.(2014) [3] reported a single case of CHS. The clinical
features of this syndrome include partial albinism, photo-
sensitivity, severe recurrent bacterial infections, bleeding
diasthesis, and late onset neurological manifestations (cen-
tral and peripheral neuropathies, sensory loss, muscle
weakness, parkinsonism, cerebellar ataxia, and cognitive
impairment) [4,5]. Approximately 85% of cases develop a
fatal accelerated phase characterized by pancytopenia,
72 I. Maaloul et al.hemophagocytosis, and marked infiltration of organs by
lymphocytes, leading to multi-organ dysfunction [6].
Owing to the rarity of the condition and the characteristic
clinical and hematological findings, we report a case of Che-
diak–Higashi syndrome, which presented as accelerated phase.
Case report
The patient is a 2-year-old male that presented with a
month-long history of fever, abdominal distension, andFigure 2 Bone marrow aspirate (A–C) and peripheral blood (D) sm
granules.
Figure 1 Face of the patient. Note skin hypopigmentation
and blond hair.cough. There was a prior history of repeated attacks of
low respiratory-tract infections and he developed
osteomyelitis at 1 year of age. He is the third child from a
consanguineous marriage, displays normal psychomotor
development, and there is no family history of the disease.
On examination, the patient was febrile, of average build,
weighed 14 kg, and had blond hair and hypopigmentation
of the skin (Figure 1). The child was anemic, with cervical
and axillary lymphadenopathy. Respiratory system examina-
tion revealed moderate respiratory distress with bilateral
coarse crepitations. The patient had a protuberant abdo-
men with massive hepatosplenomegaly. The cardiovascular
and nervous systems were normal.
Laboratory investigations showed elevated C-reactive
protein (132 mg/L), hyponatremia (124 mmol/L), high fer-
ritin levels (2685 ng/mL), low fibrinogen levels (<1.5 g/L),
and hypertriglyceridemia (3.57 mmol/L). The relevant
hematological findings were hemoglobin 5.2 g/dL, leucope-
nia at 3.56  109/L, and thrombocytopenia (Platelet count
26  109/L). Peripheral blood smear showed several abnor-
mal giant granules in most leukocytes. Bone marrow aspi-
rate revealed prominent granules within the lymphocytes
and myeloid cells (Figure 2). Phagocytosis of red blood cells
and red-blood-cell precursors hemophagocytosis was also
observed (Figure 3).
The patient fulfilled the diagnostic criteria for
hemophagocytic lymphohistiocytosis (HLH), e.g., prolonged
fever, splenomegaly pancytopenia, high ferritin levels, low
fibrinogen levels, hypertriglyceridemia, and hemophagocy-
tosis. Thus, the diagnosis of accelerated phase of CHS wasear showing myeloid precursor and lymphocytes with abnormal
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tion, blond hair) and hematological findings (giant azurophi-
lic granules in leukocytes).Figure 3 Bone marrow aspirate showing hemophagocytosis.
Figure 4 Microscopic examination of the hair shaft shows a
typical pattern of evenly distributed, regular melanin granules
larger than those seen in normal hairs (hematoxylin–eosin,
original magnification 400).
Figure 5 Chest tomography showingBlood and urine cultures were negative. Serologies of
Epstein–Barr virus, cytomegalovirus, and Aspergillus were
negative. Because of recurrent and severe infections, we
initiated immune-system investigation. The patient had nor-
mal immunoglobulin levels and T and B cells (CD3, CD4,
CD8, and CD19) were examined using flow cytometry, how-
ever, chemotaxis of natural killer cells was not studied.
Optical microscopy examination of the hair showed groups
of pigment scattered along the length of the hair shafts,
contrasting with the normal pattern of fine, diffuse pigmen-
tation (Figure 4). Chest X-ray showed opacities in interest-
ing bilateral lower zones. Chest computed tomography
showed two cavitary lesions of the middle right pulmonary
lobe (Figure 5). Abdominal ultrasound revealed hep-
atosplenomegaly with a normal echo pattern.
The child was treated with ceftazidime, Vancomycin,
and fluconazole. He received high doses of intravenous gam-
maglobulin (1 g/kg per day for 2 days). He also received
multiple transfusions, including platelets and packed red
blood cells for anemia. He died 7 days after admission
because of status epilepticus and multi-organ failure.
Discussion
CHS was first described over 60 years ago by Beguez-Cesar
(1943) [7] in three siblings bearing the main clinical features
of neutropenia and abnormal granules in leukocytes. Che-
diak, a Cuban hematologist, reported another case in 1952
[8] and in 1954, Higashi, a Japanese pediatrician, described
a series of cases finding misdistribution of myeloperoxidase
in the neutrophilic granules of affected patients [9]. CHS is a
rare disease (approximately 500 cases reported worldwide),
the prevalence and incidence of which are unknown. In a
nationwide survey in Japan, 15 patients were diagnosed dur-
ing a period of 11 years (2000–2010), indicating that one or
two patients with CHS were diagnosed each year [2].
The mean age of onset is 5.85 years, however, most
patients die before age 10. In patients that do survive
beyond childhood, neurological problems persist and/or
increase in magnitude [10].cavitary lesions in the right lung.
74 I. Maaloul et al.CHS is characterized by partial oculocutaneous albinism,
repeated infections, and pathognomonic abnormal giant
granules in neutrophils, lymphocytes, monocytes, and
platelets. Patients develop recurrent infections that most
commonly involve the skin and respiratory system.
Staphylococcus aureus and beta-hemolytic Streptococcus
are the predominant organisms. Viral and fungal infections,
however, have also been described [11]. Increased suscepti-
bility to recurrent infections is attributed to defects in
T-cell cytotoxicity and natural killer function and defects
in granulocyte chemotaxis and bactericidal activity [12].
The accelerated phase is observed in 85% of individuals
and can occur at any age, including shortly after birth or
within several years. Clinical manifestations include fever,
lymphadenopathy, hepatosplenomegaly, anemia, neutrope-
nia, thrombocytopenia, and neurological abnormalities [10].
Originally thought to be a malignancy resembling lymphoma,
the accelerated phase is now known to be an HLH character-
ized by multi-organ inflammation. The accelerated phase
and its complications are the most common cause of mortal-
ity in individuals with CHS [11]. Prognosis associated with the
accelerated phase is poor. In an Indian study of five children
with CHS, accelerated phase was seen in three cases, with all
three resulting in fatal outcomes [13].
Clinical and laboratory findings by Farhoudi et al. (2003)
[14] in six cases of CHS reported hypopigmentation of the
skin, silvery hair, photophobia, and nystagmus observed in
all patients, a history of recurrent infections in four patients,
and accelerated-phase progression in three patients.
Roy et al. (2011) [13] studied the clinico-hematological
profile of five cases of CHS, reporting that all patients had
silvery hair, partial albinism, photophobia, and recurrent
skin and/or chest infection, with three of them (50%) pre-
senting an accelerated phase.
Of the 15 patients enrolled in the Japanese study [2], 10
(67%) had recurrent bacterial infections, five (33%) devel-
oped life-threatening HLH, and one patient had complicated
malignant lymphoma. Our patient had hypopigmented skin,
blond hair, a history of recurrent low respiratory tract infec-
tions, and had developed osteomyelitis 1 year ago.
The genetic hallmark of CHS is mutations in the CHS1/
LYST gene located on chromosome 1q42–43 [15]. Mutations
of this gene result in a defect in granule morphogenesis in
multiple tissues [4]. The gene encodes a protein called the
lysosomal trafficking regulator [16] which regulates the
synthesis, transport, and fusion of cytoplasmic vesicles.
The abnormalities observed in these vesicles result in grossly
enlarged and nonfunctional lysosomes, which are identified
during cytology as giant coalesced azurophilic granules
present mostly in granulocytes and monocytes, but also
fibroblasts, melanocytes, astrocytes, Schwann cells, and
hematopoietic cells [16]. These granules are specific to
CHS and their presence in granulocytes from peripheral
blood and bone marrow is the basis of diagnosis [4].
Clinical CHS phenotypes correlate with molecular geno-
types. CHS patients with deletions in the LYST gene usually
present with a fulminant accelerated phase early in life,
whereas, those with missense mutations have a better prog-
nosis, characterized by the absence of an accelerated phase
and no neurological involvement [17]. Our patient had a
rapidly fatal course, thus, genetic analysis has not been
undertaken.The only treatment that cures the hematologic and
immunologic defects is allogenic hematopoietic stem cell
transplantation (HSCT), but this therapy does not prevent
the progressive neurological dysfunction frequently
observed during long-term follow up [1,11].
A conditioning regimen, described in detail by Haddad
et al. (1995) [18], generally includes a combination of etopo-
side, busulfan, and cyclophosphamide. The current standard
of care is HSCT as soon as the diagnosis is confirmed and the
accelerated phase has either been ruled out or is in remis-
sion. The most favorable outcome is achieved when HSCT
is performed prior to development of the accelerated phase.
If signs of the accelerated phase are present,
hemophagocytosis must be brought into clinical remission
before HSCT can be performed. Guidelines for treatment
of the accelerated phase, revised in 2004 [19], are the same
as those for familial hemophagocytic lymphocytic lympho-
histiocytosis. Combination therapy consists of etoposide,
dexamethasone, and cyclosporine A. Remission is achieved
in 75% of individuals within 8 weeks [20] however, relapses
are common and response to treatment declines over time.
Once remission occurs, prompt HSCT is recommended.
Conclusion
CHS is a rare disease with a varied spectrum of clinical pre-
sentation and investigation findings. The prognosis of the
accelerated phase is poor. HSCT is the only curative treat-
ment for hematological and immunological disorders. We
emphasize the need for early diagnosis on basis of charac-
teristic clinical findings and diagnostic laboratory examina-
tions, which leads to early transplantation before
development of the accelerated phase.Conflicts of interest
The authors declare no conflicts of interest.References
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